Every material Form 8-K Ligand Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ligand reported third-quarter 2026 results on October 29, 2026. Royalty revenue rose 51% to $70.3 million, helped by the XOMA acquisition, but total revenues and income fell 32% to $78.7 million against a prior-year period that included Pelthos divestiture income, and the company posted a GAAP net loss of $28.5 million. Ligand raised its full-year adjusted EPS guidance while reaffirming its revenue guidance, but the company's adjusted EPS excludes items such as share-based compensation and mark-to-market investment losses that affected GAAP results.
Third-quarter royalty revenue rose 51% year-over-year to $70.3 million, while total revenues and income fell 32% to $78.7 million from $115.5 million, largely due to $53.1 million of prior-year Pelthos income.
GAAP net loss was $28.5 million, or $1.43 per share, versus GAAP net income of $117.3 million, or $5.68 per diluted share, a year earlier; the quarter included $39.5 million of pre-tax investment losses.
Third-quarter adjusted EPS was $2.67, compared with $3.09, a decrease of 14%.
2026 adjusted EPS guidance was raised to approximately $9.50 to $9.75 from $9.00 to $9.50; total revenue guidance of $270 million to $310 million was reaffirmed.
Ligand reported second-quarter 2026 total revenue of $63.7 million, up 34% from a year earlier, and GAAP net income of $48.5 million, or $2.22 per diluted share, compared with $4.8 million, or $0.24, in the prior-year quarter. The company raised the low end of its 2026 adjusted EPS guidance to $9.00 to $9.50 and kept its revenue guidance unchanged, which shareholders may weigh against the non-cash gain that boosted GAAP results.
Q2 2026 total revenue was $63.7 million vs. $47.6 million; royalties were $48.0 million vs. $36.4 million.
GAAP net income was $48.5 million ($2.22 per diluted share), including a $35.7 million non-cash gain tied to Pelthos Therapeutics investments.
Adjusted EPS guidance is now $9.00 to $9.50 (previously $8.50 to $9.50); 2026 total revenue guidance of $270 million to $310 million is reaffirmed.
The $700 million 0.00% convertible notes due 2031 closed June 25, 2026; the XOMA Royalty acquisition closed July 14, 2026, with holders receiving $39.00 in cash per share plus a CVR.
Ligand Pharmaceuticals completed its merger with XOMA Royalty on July 14, 2026, paying $39.00 per share in cash plus one contingent value right (CVR) per share, for a total equity value of approximately $739 million. In connection with the closing, Ligand entered an amended credit agreement providing a $125.0 million revolving credit facility maturing September 12, 2028. Ligand expects the deal to be immediately accretive, but CVR holders may receive no payment, depending on the outcome of pending litigation at XOMA Royalty.
Consideration: $39.00 per XOMA Royalty share in cash plus one CVR per share, with total equity value of approximately $739 million
Ligand expects the deal to add approximately $0.50 per share to projected 2026 adjusted EPS and $1.50 per share to projected 2027 adjusted EPS
Amended Credit Agreement provides a $125.0 million revolving credit facility maturing September 12, 2028, secured by certain collateral and guaranteed by material domestic subsidiaries
Ligand will provide an updated 5-year outlook at its Investor Day on December 8, 2026
Ligand completed a private offering of $700.0 million of 0.00% convertible senior notes due September 15, 2031, including the full exercise of a $75.0 million option for additional notes. Net proceeds were approximately $678.2 million, with about $72.9 million used for convertible note hedge transactions and about $60.0 million used to repurchase 228,859 shares of common stock at $262.17 per share. The company said remaining proceeds will be used for general corporate purposes, including the previously announced acquisition of XOMA Royalty Corporation, and the notes add $700.0 million of senior unsecured debt.
$700.0 million principal of 0.00% convertible senior notes due September 15, 2031, closed June 25, 2026
Initial conversion price of about $334.27 per share, a premium of about 27.5% to the June 22, 2026 closing price
Net proceeds of about $678.2 million; about $72.9 million for note hedges and about $60.0 million to repurchase 228,859 shares at $262.17
Company may not redeem the notes before September 21, 2029
Ligand Pharmaceuticals announced a proposed private placement of $550 million in convertible senior notes due 2031, subject to market conditions, and amended its credit agreement to permit the notes and set new minimum Consolidated EBITDA levels. The company plans to use up to $75 million of net proceeds to repurchase common stock from certain note purchasers, and the interest rate and conversion terms will be set at pricing.
Proposed $550 million aggregate principal of convertible senior notes due September 15, 2031, offered privately to qualified institutional buyers; initial purchasers may buy up to an additional $82.5 million within a 13-day option period
Up to $75 million of net proceeds may be used to repurchase common stock from certain note purchasers in privately negotiated transactions
Fourth Amendment to the Credit Agreement sets minimum Consolidated EBITDA of $100 million for the four quarters ending June 30, 2026 through March 31, 2027, and $150 million for later periods
At its June 5, 2026 annual meeting, Ligand Pharmaceuticals stockholders elected all eight director nominees to terms expiring in 2027 and approved an amended and restated 2002 Stock Incentive Plan. Stockholders also ratified Ernst & Young LLP as auditor for fiscal 2026 and approved a non-binding advisory vote on executive pay. The filing reports voting results only and does not report financial results.
All eight director nominees were elected, including Jason M. Aryeh, Todd C. Davis and Martine Zimmermann, Pharm.D.
Proposal 4 to approve the amended and restated 2002 Stock Incentive Plan passed with 16,643,281 votes for and 870,556 against.
Ernst & Young LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026, with 18,526,515 votes for.
Non-binding say-on-pay proposal was approved with 16,497,712 votes for and 1,021,948 against.
Ligand Pharmaceuticals disclosed that on May 16, 2026 it, XOMA Royalty and its merger subsidiary signed Amendment No. 1 to the merger agreement first announced April 27, 2026. The amendment adds XOMA Royalty Holdings Corporation (HoldCo) as a party, which is tied to a holding company reorganization in which HoldCo would become a wholly owned Ligand subsidiary. The filing does not state a deal value or new terms beyond this change.
Merger Agreement with XOMA Royalty Corporation first entered into on April 27, 2026
Amendment No. 1 dated May 16, 2026 adds HoldCo as a party to the agreement
HoldCo will survive the merger as a wholly owned subsidiary of Ligand, following a holding company reorganization under Nevada law
XOMA Royalty stockholder approval and regulatory approvals are among the conditions to closing
Ligand reported first-quarter 2026 total revenue of $51.7 million, up 14% from $45.3 million a year earlier, driven by royalties of $43.0 million. The GAAP net loss narrowed to $13.3 million, or $0.67 per share, from $42.5 million, or $2.21 per share, but the company also recorded a $49.2 million non-cash loss on its Pelthos investments. Ligand reaffirmed its 2026 guidance, which was raised on April 27, 2026 to reflect the pending XOMA Royalty acquisition expected to close in the third quarter of 2026.
Total revenue $51.7 million vs. $45.3 million; royalties $43.0 million vs. $27.5 million (up 56%)
Captisol sales fell to $8.7 million from $13.5 million, due to the timing of customer orders
Adjusted net income $34.6 million, or $1.63 per diluted share, vs. $26.6 million, or $1.33, a year earlier
2026 guidance reaffirmed: adjusted EPS $8.50 to $9.50, royalty revenue $225 million to $250 million, total revenue $270 million to $310 million
On April 27, 2026, Ligand Pharmaceuticals agreed to acquire XOMA Royalty Corporation for $39.00 per share in cash plus one contingent value right per share, for a total equity value of approximately $739 million. Ligand raised its 2026 revenue and adjusted EPS guidance at the same time. The deal requires XOMA Royalty stockholder approval and Hart-Scott-Rodino clearance and is expected to close in the third quarter of 2026.
Cash price of $39.00 per share; each CVR entitles holders to a portion of 75% of net proceeds from XOMA's litigation with Janssen Biotech over TREMFYA.
Ligand raised 2026 revenue guidance to $270 million to $310 million (from $245 million to $285 million) and adjusted EPS guidance to $8.50 to $9.50 (from $8.00 to $9.00).
XOMA Royalty must pay a $40,000,000 termination fee in specified circumstances; the merger outside date is January 26, 2027.
Entities affiliated with BVF Partners, holding about 21% of XOMA Royalty common stock, agreed to support the transaction.
Ligand reported fourth quarter 2025 total revenue of $59.7 million, up 39% from a year earlier, and GAAP net income of $44.8 million, or $2.12 per diluted share, compared with a net loss in the prior-year quarter. For the full year, revenue rose to $268.1 million from $167.1 million, and the company reiterated its 2026 guidance of $245 million to $285 million in total revenue and $8.00 to $9.00 in adjusted earnings per diluted share.
Q4 2025 royalties were $50.5 million, up 45% from $34.8 million, driven mainly by Filspari, Capvaxive and Ohtuvayre sales.
Full-year 2025 GAAP net income was $124.5 million, or $6.13 per diluted share, versus a net loss of $4.0 million in 2024.
Full-year 2025 research and development expenses rose to $81.2 million from $21.4 million, including a $44.3 million one-time charge tied to the Castle Creek financing and a $17.8 million charge tied to Orchestra BioMed.
2026 guidance calls for royalty revenue of $200 million to $225 million, Captisol sales of $35 million to $40 million and contract revenue of $10 million to $20 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ligand Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →